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Purpose: Endoscopic papillectomy (EP) is currently employed for the treatment 
of ampullary adenoma. This study aimed to evaluate the clinical, endoscopic, and 
histologic characteristics related to complications and long-term outcomes of EP. 
Materials and Methods: Thirty-nine patients underwent EP for ampullary adeno-
ma. Patients were grouped according to the occurrence of procedure-related com-
plications: no complication group (n=28) and complication group (n=11). Results: 
The overall complication rate was 28.2%. The most common complication was 
EP-related pancreatitis (n=7). Amylase (p=0.006) and lipase levels (p=0.007), 24 
hours after EP, were significantly higher in the complication group, however, these 
levels did not differ at earlier times. As the tumor progressed from adenoma to 
cancer, the complete resection was significantly lessened (p=0.032). The duration of 
antiprotease injection during the hospital stay was significantly longer (p=0.017) 
and the transfusion requirements were significantly higher (p=0.018) in the com-
plication group. During a median follow-up of 15 months, three lesions (10.3%) 
recurred among patients with complete resection (n=29) and five lesions (12.8%) 
recurred among enrolled patients. One patient with progressive recurrence from 
low-grade dysplasia to adenocarcinoma was noted during a follow-up of 22 
months. Conclusion: If symptoms are present, amylase and lipase levels, 24 hours 
after EP, could help predict possible EP-related pancreatitis. Histologic diagnosis 
through resected specimens may result in complete resection. Patients with com-
plications need a longer duration of antiprotease injection during their hospital stay 
and more transfusions. The recurrence rate was not significantly high in complete-
ly resected cases, however, there was a possibility of progressive recurrence.
Key Words:   Ampullary adenoma, endoscopic papillectomy, endoscopic retro-
grade cholangiopancreatography, complication 
INTRODUCTION
Ampullary adenomas are rare with a prevalence of 0.04% to 0.12% in autopsy 
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bloc resection was defined as resection in a one-piece fash-
ion with no residual tumor viewed endoscopically. Com-
plete resection was defined as resection in the absence of 
any remnant lesion or recurrence in control biopsies at the 
end of the study regardless of the number of treatment ses-
sions.6,10 Endoscopic success was defined as total removal 
via excision, irrespective of the number of sessions required 
for removal, and absence of recurrence or recurrence during 
the follow-up period, treated sufficiently by EP.11 Clinical 
outcomes included duration of antiprotease injection during 
the hospital stay, transfusion requirement, length of hospital 
stay, mortality, and recurrence.
The pre-procedural diagnosis of ampullary adenoma was 
obtained for each patient by forceps biopsy. Endoscopic ultra-
sound (EUS), transpapillary intraductal ultrasound (IDUS), 
ERCP, and computed tomography or magnetic resonance im-
age were applied for the assessment of the extent of the tumor.
An indication for EP was based on EUS, IDUS, and ERCP 
findings that showed that the tumor had not infiltrated the 
bile or pancreatic ducts and that the adenoma or cancer in-
vasion was confined to the mucosa.6,10 Patients with inva-
sive carcinoma, metastatic disease, coagulation abnormali-
ties, or severe concomitant disorders were not indicated for 
ampullectomy. Patients with ampullary adenoma in famil-
iar adenomatous polyposis were excluded. Written informed 
consent was obtained from all patients. This study was ap-
proved by the Institutional Review Board of Yonsei Uni-
versity College of Medicine, Korea.
Procedure
EP was performed by five expert endoscopists with patients 
under sedation. The entire procedure was carried out under 
fluoroscopic guidance using a side-view duodenoscope (TJF 
260; Olympus, Tokyo, Japan). EP was performed using one 
of the following methods: 1) snare papillectomy or 2) endo-
scopic mucosal resection (EMR). For en block resection, we 
performed EP by grasping the adenoma at the base with a 
standard polypectomy snare and applying an Endocut current 
effect 2 using an ERBE generator. The EMR was performed 
for only periampullary portion, because the submucosal in-
jection of papilla can also make the lesion difficult to capture 
using a snare.12 Small, remnant lesions unamenable to snare 
resection were either removed by endoscopic forceps or ful-
gurated by argon plasma coagulation (APC; ERBE Elektro-
medizin, Germany). The placement of a pancreatic stent was 
routinely performed. The application of biductal sphincterot-
omy or biliary stent was individualized in each case. 
studies,1 and may occur either sporadically or in patients 
with familiar adenomatous polyposis.2 Ampullary adeno-
mas should be removed completely, because they can po-
tentially undergo an adenoma-carcinoma sequence with a 
transformation rate to carcinoma of up to 30%;3,4 biopsy of 
ampullary tumors using endoscopic forceps revealed an 
alarming 30% false-negative rate for detecting carcinoma 
in situ and invasive carcinoma.5
Surgical resection, including pancreatoduodenectomy 
and transduodenal resection, has been considered the stan-
dard treatment for ampullary adenomas.6 Recently, endo-
scopic papillectomy (EP) was employed for the treatment 
of ampullary adenomas as a feasible alternative procedure, 
because of considerable perioperative morbidity and mor-
tality of surgical resection.6,7 The main concerns about EP 
are procedure-related complications and long-term treat-
ment outcomes. The overall complication rate related to EP 
in previous studies ranged from 8% to 32%,8,9 and the re-
currence rate was reported to be 2.8% to 15% during medi-
an follow-ups of 14 to 43 months in earlier studies.7,10 De-
spite relatively high complication and recurrence rates, 
studies of the characteristics of complications and long-term 
outcomes of EP are limited due to the rarity of the disease.
This study aimed to evaluate the clinical, endoscopic, and 
histologic characteristics of complications after EP and 




From September 2006 to April 2012, 39 consecutive pa-
tients with ampullary adenoma underwent EP at a high-vol-
ume tertiary referral center. During the same period, 3332 
endoscopic retrograde cholangiopancreatography (ERCP) 
procedures, including 2437 diagnostic and 895 therapeutic 
procedures, were performed. Thus, 1.2% of all ERCPs and 
4.4% of therapeutic ERCPs were carried out for EP. Includ-
ed patients were grouped according to the occurrence of 
procedure-related complications: no complication group 
(without complication, n=28) and complication group (with 
complication, n=11). 
We retrospectively analyzed the clinical, laboratory, en-
doscopic, and histologic data which were prospectively re-
corded. Treatment outcomes were categorized as endoscop-
ic and clinical. Endoscopic outcomes included en block 
resection, complete resection, and endoscopic success. En 
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scopical evidence of bleeding after completion of the pro-
cedure. The clinical or endoscopic evidence comprised the 
following: 1) fresh hematemesis or fresh blood passing 
from the nasogastric tube; 2) passage of fresh melena or he-
matochezia with evidence of bleeding (a systolic blood 
pressure <100 mm Hg, a heart rate >100 bpm, or a drop in 
hemoglobin level of >2 g/dL within 24 h); and 3) bleeding 
demonstrated by endoscopy.
Follow-up endoscopy with forceps biopsy was scheduled 
after 3 to 6 months and at yearly intervals thereafter. A second 
endoscopy was not performed routinely. If the resected lesion 
recurred and additional endoscopic treatment was possible, 
endoscopic treatment was performed every 2 to 3 months un-
til there was no residual adenoma, with surveillance every 6 to 
12 months for the next 2 years according to the recommenda-
tions.16 When the patient had a small lesion with tubular ade-
noma, the interval of endoscopic surveillance was increased 
to 2 or 3 years gradually. Surgical resection was done if addi-
tional endoscopic treatment was not feasible.
 
Statistical analysis
Statistical analysis included the chi-square test, Fisher’s ex-
act test, and Mann-Whitney U test. Results were presented 
as proportions, or median with range (minimum-maximum) 
as indicated. Kaplan-Meier’s test and log-rank test were 
performed for the evaluation of recurrence rate and com-
parison of recurrence rate between two groups, respective-
ly. A p value <0.05 was considered statistically significant. 
Statistical analysis was performed using the SAS program 
(version 9.2, SAS Institute, Cary, NC, USA).
RESULTS
 
Baseline characteristics of patients
This study included 39 patients (23 men and 16 women; 
median age 62.0 years, range 34.0-88.0 years). There were 
no significant differences in baseline characteristics, includ-
ing age, gender, and the use of antiplatelets, anticoagula-
tion, and comorbidities, between the no complication group 
(n=28) and the complication group (n=11) (Table 1). There 
was no significant difference in the distribution of five en-
doscopists between the two groups (p=0.074). 
Clinical and laboratory characteristics
Clinically, the presence of symptoms, including pancreatitis 
prior to EP was similar in the two groups. In laboratory char-
As EP and biliary or pancreatic sphincterotomy are higher-
risk procedures for bleeding, we weighted the benefit of dis-
continuation of anti-platelets (aspirin and non-steroidal anti-
inflammatory drugs) against the risk of thromboembolic 
events. We discontinued aspirin and/or non-steroidal anti-in-
flammatory drugs for 5 to 7 days before the procedure, de-
pending on the underlying indication for antiplatelet thera-
py.13 We used antiprotease including nafamostat and gabexate 
mesylate: 50 mg of nafamostat was infused intravenously 
twice a day and 600 mg of gabexate mesylate intravenously 
once a day.
Endoscopic and histologic characteristics
We classified the macroscopic type of lesion as an exposed 
type vs. an unexposed type, based on a previous macro-
scopic classification of carcinoma of the ampulla of Vater.7 
We defined the exposed type of lesion as polypoid tumors 
protruding through the papilla into the duodenum (periam-
pullary type). The unexposed type was defined as polypoid 
tumors of the common channel without a duodenal luminal 
component (intraampullary type), or a mixed form of peri-
ampullary and intraampullary type.
Resected specimens were diagnosed according to the re-
vised Vienna classification.14 Histologic grading was classi-
fied as low-grade dysplasia (LGD), high-grade dysplasia 
(HGD), differentiated adenocarcinoma, and undifferentiat-
ed adenocarcinoma. The positivity of vertical and lateral cuts 




Complications were classified into early (pancreatitis, bleed-
ing, perforation, and others) or late (post-papillectomy ste-
nosis) onset. EP-related pancreatitis was defined according 
to consensus criteria.15 It was diagnosed if there was an ele-
vation in pancreatic enzymes of at least three times the up-
per limit of the normal range 24 hours after the procedure, 
new onset of pain in the upper abdomen, and hospitalization 
for at least 2 days. The grade of pancreatitis severity was 
also determined according to consensus guidelines; mild 
EP-related pancreatitis resulting in a hospitalization of less 
than or equal to 3 days; moderate EP-related pancreatitis re-
sulting in a hospitalization of 4 to 10 days; and severe EP-re-
lated pancreatitis resulting in a hospitalization of 11 or more 
days, leading to the development of pancreatic necrosis or 
pseudocyst, or requiring percutaneous or surgical interven-
tion. Bleeding was diagnosed if there was clinical or endo-
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the two groups (Table 3). Endoscopic characteristics includ-
ing the size and type of lesion, placement of pancreatic or bil-
iary duct stent after EP, performance of biductal sphincteroto-
my, and resection method (snare papillectomy vs. EMR) did 
not reveal any significant differences. The sizes and lengths 
of stents ranged from 5 to 8 Fr and from 5 to 7 cm, respec-
tively. The histologic diagnosis of resected specimens was 
not significantly different between the two groups (p=0.541), 
however, was associated with complete resection rate. The 
complete resection rate in LGD (n=24), HGD (n=7), ade-
nocarcinoma (n=3), and benign tissue (n=5) was 83.3%, 
42.9%, 33.3%, and 100%, respectively (p=0.032). Thus, it 
appears that as the tumor progressed from adenoma to can-
cer, the complete resection rate decreased.
Treatment outcomes
The overall en block resection rate, complete resection rate, 
and endoscopic success rate were 89.7%, 74.4%, and 92.3%, 
respectively. The overall median value of the duration of 
antiprotease injection during the hospital stay and length of 
hospital stay were 3.0 days (range 1.0-18.0 days) and 8.0 
acteristics, amylase (median 111 IU/L vs. 361 IU/L, p=0.006) 
and lipase levels (median 67 IU/L vs. 457 IU/L, p=0.007), 24 
hours after EP, were significantly higher in the complication 
group than in the no complication group. However, amylase 
and lipase levels within 24 hours after EP and other laboratory 
serologic values, including hemoglobin levels, white blood 
cell count, platelet count, aspartate transaminase, and alanine 
transaminase levels, total bilirubin, and albumin levels were 
not significantly different between the two groups.
Complications of EP
The complications of EP are summarized in Table 2. Fifteen 
complications from 11 patients (28.2%) occurred, and all 
were early complications. The most common complication 
was EP-related pancreatitis (n=7, 17.9%), followed by bleed-
ing (n=4, 10.3%) and perforation (n=2, 5.1%). Seven EP-re-
lated cases of pancreatitis were composed of grade 2 (n=5) 
and grade 3 (n=2) pancreatitis. They were successfully man-
aged with medical treatment, including fasting, intravenous 
hydration, and antiprotease injection. No necrotizing pancre-
atitis or pancreatic pseudocysts developed during EP-related 
pancreatitis. Four patients experienced procedure-related 
bleeding, which was managed with endoscopic clips, electric 
coagulation, or APC. Two patients with perforations were 
managed with endoscopic clips and medical treatments. Two 
patients developed pneumonia after the procedure, which 
was managed without further complications. No cholangitis 
or biliary stenosis occurred. None of the patients underwent 
any surgeries for complication management.
Endoscopic and histologic characteristics
We analyzed the endoscopic and histologic characteristics of 
Table 1. Baseline Characteristics of 39 Patients Underwent Endoscopic Papillectomy for Ampullary Adenoma
Characteristic No complication (n=28) Complication (n=11) p value
Age, yrs*   65 (37-88)       57 (34-87) 0.301
Male sex (%) 17 (60.7)      6 (54.5) 0.734
Alcohol (%)   7 (25.0)      5 (45.5) 0.262
Smoking (%)   6 (21.4)      4 (36.4) 0.424
Use of antiplatelets (%)   3 (10.7)      2 (18.2) 0.609
Use of anticoagulation (%) 1 (3.6)    1 (9.1) 0.490
Comorbidities (%) 0.954
    Diabetes mellitus   6 (21.4)      2 (18.2)
    Hypertension   9 (32.1)      3 (27.3)
    Chronic liver disease 2 (7.1) 0 (0)
    Cardiac disease   3 (10.7)    1 (9.1)
    Renal disease 2 (7.1) 0 (0)
    Cancer   6 (21.4)    1 (9.1)
*Data were expressed as median with range.
Table 2. 15 Complications of Endoscopic Papillectomy Which 
Occurred in 11 Patients
Complication No. % 
Pancreatitis 7 17.9
    Grade of pancreatitis
        Grade 1 0
        Grade 2 5
        Grade 3 2
Bleeding 4 10.3
Perforation 2   5.1
Others 2   5.1
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rence sometimes differed from the prior histology of the re-
sected specimen. In one patient with previously resected 
HGD, LGD occurred. In another patient with resected 
LGD, adenocarcinoma occurred. In the latter case, a patho-
logical examination revealed that the resection margin was 
clear at the time of ampullectomy, but pancreaticoduode-
nectomy was performed 22 months later, because of the oc-
currence of adenocarcinoma. Additionally, the recurrence 
was not associated with the initial size of the lesion, as the 
lesions without recurrence and with recurrence did not 
show a significant difference in lesion size (p=0.281). 
DISCUSSION
The present study focused on the procedure-related compli-
cations and long-term treatment outcomes of EP. Previous 
EP studies reported complication rates that ranged from 8% 
days (range 4.0-24.0 days), respectively. Thirty-two of the 
enrolled patients (82.1%) received anti-protease agents. 
There was no mortality in the present study. Treatment out-
comes of the two groups are listed in Table 4. The en block 
resection rate, complete resection rate, and endoscopic suc-
cess rate did not differ significantly between the two groups. 
Clinically, the duration of antiprotease injection during the 
hospital stay was significantly longer (median 2.0 days vs. 
5.0 days, p=0.017) and the transfusion requirements were 
significantly higher (0% vs. 27.3%, p=0.018) in the compli-
cation group than the no complication group. The hospital 
stay tended to be longer (median 6.5 days vs. 9.0 days, p= 
0.083) in the complication group. During a median follow-
up period of 15 months (range 1-25 months), three lesions 
(10.3%) recurred among patients with complete resection 
(n=29) and five lesions (12.8%) recurred among enrolled 
patients. In three HGD lesions and two LGD lesions, recur-
rence occurred. However, the histology at the time of recur-
Table 3. Endoscopic and Histologic Characteristics of No Complication Group and Complication Group
Characteristic No complication (n=28) Complication (n=11) p value
Size of lesion (mm)* 15 (4-40)     11 (8-20) 0.354
Exposed type of lesion (%) 22 (78.6)      6 (54.5) 0.234
Pancreatic duct stent after EP (%) 19 (67.9)      6 (54.5) 0.478
Biliary duct stent after EP (%) 11 (39.3)      2 (18.2) 0.276
Biductal sphincterotomy (%)   9 (32.1)      4 (36.4) 1.000
Resection method (%) 0.477
    Snare papillectomy 16 (57.1)      8 (72.7)
    Endoscopic mucosal resection 12 (42.9)      3 (27.3)
Histology of resected specimen (%) 0.541
    Low-grade dysplasia 15 (53.6)      9 (81.8)
    High-grade dysplasia   6 (21.4)    1 (9.1)
    Adenocarcinoma   3 (10.7) 0 (0)
    Benign tissue   4 (14.3)    1 (9.1)
EP, endoscopic papillectomy.
*Data were expressed as median with range.
Table 4. Treatment Outcomes of No Complication Group and Complication Group
Treatment outcome No complication (n=28) Complication (n=11) p value
En block resection (%)  24 (85.7)  11 (100) 0.309
Complete resection (%)  19 (67.9)  10 (90.9) 0.228
    Vertical cut end-positive    6 (21.4)    1 (9.1) 0.649
    Lateral cut end-positive    3 (10.7)    1 (9.1) 1.000
Endoscopic success (%)  27 (96.4)    9 (81.8) 0.187
Duration of antiprotease injection (day)* 2.0 (1.0-18.0) 5.0 (1.0-13.0) 0.017
Transfusion requirement    0 (0)    3 (27.3) 0.018
Hospital stay (day)* 6.5 (4.0-24.0) 9.0 (7.0-18.0) 0.083
Mortality (%)    0 (0)    0 (0)
Recurrence (%)†    1 (5.3)    2 (20.0) 0.480
*Data were expressed as median with range.
†Data were evaluated among patients with completely resected lesions (n=29).
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Histologic diagnosis of resected specimens was associat-
ed with a statistical difference in complete resection but not 
with complications in a previous study.21 Our study showed 
that as the tumor progressed from LGD to adenocarcinoma, 
the complete resection rate decreased. We attribute this in-
teresting finding to an underestimation of the extent of the 
malignant margin, caused by endoscopist’s prejudice based 
on histology using forceps biopsy with poor sensitivity.5,22 
Additionally, the biology of the tumor might affect the com-
plete resection rate. Due to unique location of the tumor 
and associated complications, it is difficult to resect the tu-
mor with sufficient margins, thus missing lateral and verti-
cal spread of the tumor. Therefore, in cases with HGD and 
adenocarcinoma, endoscopists should evaluate previously 
undiagnosed intraductal extension using a cholangiogram 
and a pancreaticogram immediately prior to resection and 
try to resect the tumor with as much a margin as possible.
Complications of EP in terms of treatment outcomes have 
not been evaluated previously. Our study showed that the 
occurrence of complications might not change the endo-
scopic treatment outcomes. In contrast, the complications 
affected the clinical outcomes, including a longer duration 
of antiprotease injection during the hospital stay and a more 
required transfusion. In addition, the complication group 
tended to have a longer hospital stay than the no complica-
tion group. We made the decision to discharge patients after 
EP, based on symptoms, signs, and other evidence includ-
ing laboratory evaluation. We had a policy of early discharge 
after EP, mainly due to the medical cost burden on patients, 
however, the heterogenous composition of five endosco-
pists might have affected individualized decisions for dis-
charge and the length of hospital stay in the present study. 
The recurrence rate in the present study was 10.3% among 
patients with complete resection and 12.8% among enrolled 
patients during a median follow up of 15 months, similar to 
earlier studies, which ranged from 2.8% to 15%.7,10 The oc-
currence of complications may not change the recurrence rate.
Interestingly, one patient with progressive recurrence was 
noted in this study. The histology of completely resected 
specimen was LGD, and the histology of surgically resect-
ed specimen of the recurred lesion 22 months after EP was 
differentiated adenocarcinoma that invaded the duodenum 
and distal pancreatic duct. This is the first report of progres-
sive recurrence in ampullary adenoma, though malignant 
recurrence from possibly remnant malignant foci in the am-
pullary adenoma cannot be excluded. Although progressive 
recurrence is very rare, clinicians should be aware of the pos-
to 32%,8,9 similar to 28.2% among enrolled patients in our 
study. Complications included EP-related pancreatitis, bleed-
ing, and perforation as early complications, and pancreatic 
duct stenosis as a late complication. 
Acute pancreatitis is the most common major complica-
tion of ERCP, accounting for substantial morbidity and oc-
casional death.17,18 In the present study, EP-related pancre-
atitis occurred in 17.9% of patients, presenting mainly as 
moderate to severe, and accompanying a prolonged hospi-
tal stay, whereas EP-related pancreatitis occurred in 5% to 
15% of patients, mainly as a mild form as seen in a previous 
study.10 To predict the possible occurrence of EP-related 
pancreatitis, clinicians routinely measure amylase and lipase 
levels, usually within 24 hours of EP. However, a transient 
elevation of amylase and lipase levels often occurs after EP. 
To differentiate such a transient elevation of amylase and li-
pase levels from EP-related pancreatitis, we serially tested 
amylase and lipase levels within 24 hours as well as 24 
hours after EP. Significant differences in amylase and lipase 
levels between the two groups were noted only 24 hours af-
ter EP. Therefore, we recommend a follow-up measurement 
of amylase and lipase levels 24 hours after EP to predict 
EP-related pancreatitis in patients with significant abdomi-
nal pain.
Currently, the preventive effects of a pancreatic stent for 
EP-related pancreatitis are not well established.6,19 The only 
prospective, randomized, controlled trial evaluating the role 
of a prophylactic pancreatic stent for the reduction of EP-
related pancreatitis showed a statistically significant decrease 
in the rate of EP-related pancreatitis in the stent group.20 In 
our study, we placed the pancreatic stent in 64.1% of pa-
tients, and found that the occurrence of EP-related pancre-
atitis between unstented (n=14) and stented lesions (n=25) 
was not significantly different (14.3% vs. 20.0%, p=1.000). 
A large-scale study is needed to confirm the protective ef-
fect of pancreatic stent for pancreatitis after EP.
The submucosal injection may help predict the presence 
of malignancy and reduce the risk of bleeding and perfora-
tion.8 In our study, submucosal injection was performed in 
38.5% of patients. Four bleeding complications and two 
perforation complications occurred, but only in cases with-
out submucosal injection. Lesions without submucosal in-
jection (n=24) tended to have more bleeding and perfora-
tion complications than lesions with submucosal injection 
(n=15) (25% vs. 0%, p=0.065). Thus, submucosal injec-
tions during EP seem to reduce the risk of bleeding and per-
foration.
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sibility of malignant foci in the ampullary adenoma when re-
current lesion shows progressive histology from LGD to 
HGD. Even if the histology of the resected specimen was 
LGD, careful and regular follow up is still needed.
This study had some limitations. First, this is a single-
center, retrospective study. Second, the number of enrolled 
patients was small, because of the rarity of disease. Third, 
heterogeneity in resection methods is also a possible limita-
tion. In addition, because the complication group included 
heterogenous complications, our data may not represent the 
safety and outcome of a specific complication.
In spite of these limitations, the present study had some 
important messages. This is the first study investigating the 
clinical, endoscopic, and histologic characteristics of com-
plications after EP. In addition, this is the first study of the 
clinical implications of complications after EP in terms of 
treatment outcomes and recurrence pattern.
In conclusion, if symptoms are present, amylase and li-
pase levels 24 hours after EP could help predict the possi-
bility of EP-related pancreatitis. Histologic diagnosis with 
resected specimens may be associated with complete resec-
tion. Patients with complications need longer duration of 
antiprotease injection during their hospital stay and more 
transfusions. The recurrence rate is not significantly high in 
completely resected cases, nevertheless, there is a possibili-
ty of progressive recurrence. Further studies are needed to 
reduce the complication rate of EP and increase the com-
plete resection rate at the same time.
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